Treatment with bexmarilimab and Vidaza elicited high overall response rates in both frontline and relapsed/refractory ...

The myelodysplastic syndromes (MDS) are disorders of the haematopoietic stem cells in the bone marrow, that result in a decreased production of blood cells. MDS mainly affects patients aged 70 and ...

Inside Information: BEXMAB Phase II trial met its primary endpoint in treatment-resistant High Risk MDS (r/r HR MDS) Topline read-out from the Phase II BEXMAB trial confirms earlier positive findings ...

Discover the latest findings on transplantation outcomes in Myelodysplastic Syndrome and Acute Myeloid Leukaemia from EBMT ...

TURKU, FI / ACCESS Newswire / April 15, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Inside Information: BEXMAB Phase II trial met its primary endpoint in treatment-resistant High Risk MDS (r/ ...

As the data continues to unfold, with Faron and Dr. Jalkanen at its helm, the medical community can hold its breath, hoping ...

Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the ...

Kataleya Steward is a 4-year-old from Niles looking for a blood donor as she battles Fanconi Anemia and Myelodysplastic Syndrome.

In the United States, MDS cases are reported at a rate of 4.8 per 100,000 people annually, highlighting the pressing need for effective treatment solutions. As life expectancy increases globally, the ...

MNV-201 is Minovia’s second generation mitochondrial cell therapy product composed of autologous hematopoietic stem cells enriched with ...